Sinovac regimen gets strong boost from Pfizer, AstraZeneca or J&J COVID shots - study


The study found that CoronaVac received the strongest boost from a viral vector or RNA shot, including against the Delta and Omicron coronavirus variants, researchers from Brazil and Oxford University said https://www.ox.ac.uk/news/2022-01-24-mixed-vaccine-schedules-offer-strong-booster-responses-after-two-doses-coronavac on Monday.

A third booster dose of a COVID-19 vaccine made by AstraZeneca, Pfizer-BioNTech or Johnson & Johnson increases antibody levels significantly in those who have previously received two doses of Sinovac's CoronaVac shot, a study has found.

The study found that CoronaVac received the strongest boost from a viral vector or RNA shot, including against the Delta and Omicron coronavirus variants, researchers from Brazil and Oxford University said https://www.ox.ac.uk/news/2022-01-24-mixed-vaccine-schedules-offer-strong-booster-responses-after-two-doses-coronavac on Monday.

The Star 6.6 DEAL: 35% OFF Digital Access

Monthly Plan

RM 13.90/month

RM 9.04/month

Billed as RM 9.04 for the 1st month, RM 13.90 thereafter.

Best Value

Annual Plan

RM 12.33/month

RM 8.02/month

Billed as RM 96.20 for the 1st year, RM 148 thereafter.

Follow us on our official WhatsApp channel for breaking news alerts and key updates!
Corona , Imicron Deta , Sinovac , Pfizer , AstraZeneca , J&J , Covid

Next In Business News

FBM KLCI rebounds in early trade as investors await key US inflation data
Ringgit opens higher against major currencies, easier versus US dollar
Trading ideas: Duopharma, DNeX, Dayang, Varia, Kee Ming
Corporates must enhance capital efficiency
Ringgit remains among top regional currencies, says minister
Automakers shift focus to premium lines
Kee Ming wins RM21mil DC contract
Mideast tensions spike April fuel subsidy bill
Dnex acquires 20% stake in Terengganu Inc unit
MMCS posts RM3mil net profit in 1Q26

Others Also Read